LISA RUSSELL: Open Payments
NPI 1871974865 · LAWRENCE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 30 payments from 12 companies in 2025. Trend: 2023 $284 · 2024 $230 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $157 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Gilead Sciences, Inc. | 4 | $74 |
| ABBVIE INC. | 3 | $65 |
| Lilly USA, LLC | 2 | $33 |
| Insulet Corporation | 2 | $31 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $17 |
Products named: HETLIOZ, REXULTI, VRAYLAR, FANAPT, Omnipod, VAXNEUVANCE, UBRELVY, INGREZZA.
Industry payments across KS — which companies pay providers there.
